262614-64-2

Usage

Uses

Used in Food Industry:
Benzoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-5-methoxy(9CI) is used as a preservative in the food industry to prevent the growth of bacteria, yeast, and mold. Its application helps in prolonging the shelf life of a variety of food products and maintaining their quality.
Used in Cosmetics Industry:
In the cosmetics industry, Benzoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-5-methoxy(9CI) serves as a preservative to prevent microbial contamination, ensuring the safety and stability of cosmetic products.
The addition of functional groups to benzoic acid in Benzoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-5-methoxy- (9CI) potentially enhances its preservative effectiveness and overall safety for human consumption, although further research may be required to fully understand the impact of these modifications on its properties and applications.

InChI:InChI=1/C13H17NO5/c1-13(2,3)19-12(17)14-10-6-5-8(18-4)7-9(10)11(15)16/h5-7H,1-4H3,(H,14,17)(H,15,16)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 

Downstream Products

• 1263080-75-6 C₃₉H₅₄N₄O₉ 
• 1263090-48-7 C₄₀H₅₆N₄O₉ 
• 1198473-10-7 C₁₅H₂₂N₂O₅ 

Relevant academic research and scientific papers

Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening

Mycobacterium tuberculosis (M.tb), the etiologic agent of tuberculosis, remains the leading cause of death from a single infectious agent worldwide. The emergence of drug-resistant M.tb strains stresses the need for drugs acting on new targets. Mycolic acids are very long chain fatty acids playing an essential role in the architecture and permeability of the mycobacterial cell wall. Their biosynthesis involves two fatty acid synthase (FAS) systems. Among the four enzymes (MabA, HadAB/BC, InhA and KasA/B) of the FAS-II cycle, MabA (FabG1) remains the only one for which specific inhibitors have not been reported yet. The development of a new LC-MS/MS based enzymatic assay allowed the screening of a 1280 fragment-library and led to the discovery of the first small molecules that inhibit MabA activity. A fragment from the anthranilic acid series was optimized into more potent inhibitors and their binding to MabA was confirmed by 19F ligand-observed NMR experiments.

Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases

The first steps in the selection process of a new anti-inflammatory drug for the inhaled treatment of asthma and chronic obstructive pulmonary disease are herein described. A series of novel ester derivatives of 1-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3,5-dichloropyridin-4- yl) ethanol have been synthesized and evaluated for inhibitory activity toward cAMP-specific phosphodiesterase-4 (PDE4). In particular, esters of variously substituted benzoic acids were extensively explored, and structural modification of the alcoholic and benzoic moieties were performed to maximize the inhibitory potency. Several compounds with high activity in cell-free and cell-based assays were obtained. Through the evaluation of opportune in vitro ADME properties, a potential candidate suitable for inhaled administration in respiratory diseases was identified and tested in an in vivo model of pulmonary inflammation, proving its efficacy.

Synthesis of a quinolone library from ynones

A library of 72 quinolones was synthesized from substituted anthranilic acids, using ynone intermediates. These masked β-dicarbonyl synthons allowed cyclization under milder conditions than previously reported quinolone syntheses.